Literature DB >> 10429004

Relationship among genotype, biochemical phenotype, and cognitive performance in females with phenylalanine hydroxylase deficiency: report from the Maternal Phenylketonuria Collaborative Study.

F Güttler1, C Azen, P Guldberg, A Romstad, W B Hanley, H L Levy, R Matalon, B M Rouse, F Trefz, F de la Cruz, R Koch.   

Abstract

OBJECTIVE: To examine the relationship of phenylalanine hydroxylase (PAH) genotypes to biochemical phenotype and cognitive development in maternal phenylketonuria (PKU).
METHODOLOGY: PAH gene mutations were examined in 222 hyperphenylalaninemic females enrolled in the Maternal PKU Collaborative Study (MPKUCS). A total of 84 different mutations were detected, and complete genotype was obtained in 199 individuals. Based on previous knowledge about mutation-phenotype associations, 78 of the mutations could be assigned to one of four classes of severity (severe PKU, moderate PKU, mild PKU, and mild hyperphenylalaninemia [MHP]). Then, 189 MPKUCS subjects were grouped according to the various combinations of mutation classifications. The sample sizes were large enough for statistical testing in four groups with at least one mutation that completely abolishes enzyme activity. These patients are considered functionally hemizygous.
RESULTS: The biochemical phenotype predicted from the genotype in functionally hemizygous patients was related significantly to the assigned phenylalanine level. Cognitive performance (IQ) was also significantly related to genotype. The IQ of PAH-deficient mothers with a severe PKU mutation in combination with a MHP mutation or a mild PKU mutation was 99 and 96, respectively, whereas the IQ of PKU mothers with two severe PKU mutations or with one severe and one moderate PKU mutation was 83 and 84, respectively. Of the patients with PKU, 92% had been treated during childhood. Those who were untreated or treated late had lower than average IQ scores for their group of mutation combinations. Females with moderate or mild PKU who were treated early and treated for >6 years showed IQ scores 10 points above average for their group.
CONCLUSIONS: The reproductive outcome in maternal phenylketonuria is dependent on prenatal metabolic control and postnatal environmental circumstances. Both factors depend on the intellectual resources of the mother with PKU. The significant relationship among genotype, biochemical phenotype, and cognitive performance observed in the present study is of importance for the development of an optimal strategy for future treatment of females with PKU who plan pregnancy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10429004     DOI: 10.1542/peds.104.2.258

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  13 in total

1.  Protein stability and in vivo concentration of missense mutations in phenylalanine hydroxylase.

Authors:  Zhen Shi; Jenn Sellers; John Moult
Journal:  Proteins       Date:  2011-09-21

2.  Clinical utility gene card for: Phenylketonuria.

Authors:  Johannes Zschocke; Thomas Haverkamp; Lisbeth Birk Møller
Journal:  Eur J Hum Genet       Date:  2011-09-14       Impact factor: 4.246

3.  Nutritional Management of Phenylketonuria.

Authors:  Erin L Macleod; Denise M Ney
Journal:  Ann Nestle Eng       Date:  2010-06

Review 4.  Understanding the apothecaries within: the necessity of a systematic approach for defining the chemical output of the human microbiome.

Authors:  Kirk Beebe; Brante Sampey; Steven M Watkins; Michael Milburn; Andrea D Eckhart
Journal:  Clin Transl Sci       Date:  2014-01-14       Impact factor: 4.689

Review 5.  Nutritional management of PKU with glycomacropeptide from cheese whey.

Authors:  D M Ney; S T Gleason; S C van Calcar; E L MacLeod; K L Nelson; M R Etzel; G M Rice; J A Wolff
Journal:  J Inherit Metab Dis       Date:  2008-10-29       Impact factor: 4.982

6.  Blood phenylalanine concentrations in patients with PAH-deficient hyperphenylalaninaemia off diet without and with three different single oral doses of tetrahydrobiopterin: assessing responsiveness in a model of statistical process control.

Authors:  M Lindner; G Gramer; S F Garbade; P Burgard
Journal:  J Inherit Metab Dis       Date:  2009-06-10       Impact factor: 4.982

7.  The Molecular Bases of Phenylketonuria (PKU) in New South Wales, Australia: Mutation Profile and Correlation with Tetrahydrobiopterin (BH4) Responsiveness.

Authors:  Gladys Ho; Ian Alexander; Kaustuv Bhattacharya; Barbara Dennison; Carolyn Ellaway; Sue Thompson; Bridget Wilcken; John Christodoulou
Journal:  JIMD Rep       Date:  2013-12-25

8.  Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases.

Authors:  Angel L Pey; Francois Stricher; Luis Serrano; Aurora Martinez
Journal:  Am J Hum Genet       Date:  2007-10-02       Impact factor: 11.025

9.  Effects and clinical significance of tetrahydrobiopterin supplementation in phenylalanine hydroxylase-deficient hyperphenylalaninaemia.

Authors:  G Gramer; P Burgard; S F Garbade; M Lindner
Journal:  J Inherit Metab Dis       Date:  2007-08-06       Impact factor: 4.982

10.  Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes.

Authors:  Erin L MacLeod; Sally T Gleason; Sandra C van Calcar; Denise M Ney
Journal:  Mol Genet Metab       Date:  2009-08-08       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.